Abbott cash buyout: Exact Sciences (EXAS) director paid $105 per share

Rhea-AI Filing Summary

EXACT SCIENCES CORP director Leslie Trigg disposed of all her directly held common shares back to the company in connection with its cash merger with Abbott Laboratories. One transaction returned 3,244 shares and a second returned 13,925 shares, leaving her with zero shares afterward.

Under the merger terms, each Exact Sciences common share outstanding immediately before the effective time was converted into the right to receive $105.00 in cash, without interest. Stock awards subject to vesting or other restrictions were also deemed fully vested, cancelled and converted into the same cash consideration, less applicable tax withholding.

Insights

M&A and insider-transactions analyst

Director’s entire equity position was cashed out via an issuer disposition tied to a completed cash merger.

Director Leslie Trigg reported two non-derivative transactions coded "D" (disposition to issuer), returning 3,244 and then 13,925 shares of Exact Sciences common stock to the company at a stated price of $0.00 per share. After these steps, her reported direct holdings fell to zero, indicating a full exit of this equity position.

Footnotes explain that these actions occurred at the effective time of a merger where Abbott Laboratories acquired Exact Sciences, with each common share converted into the right to receive $105.00 in cash. Equity awards subject to vesting or other restrictions were also fully vested and converted into the same cash consideration, less tax withholding. Because these dispositions arose mechanically from a previously agreed merger consideration rather than open-market trading, they carry limited signaling value about the director’s independent view of the stock.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Trigg Leslie

Role Director

Type	Security	Shares	Price	Value
Disposition	Common Stock	3,244	$0.00	--
Disposition	Common Stock	13,925	$0.00	--

Holdings After Transaction: Common Stock — 13,925 shares (Direct)

Footnotes (1)

1. On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration"). At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Trigg Leslie

(Last) (First) (Middle)

C/O EXACT SCIENCES CORP.

5508 ENDEAVOR LANE

(Street)

MADISON WISCONSIN 53719

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXACT SCIENCES CORP [ EXAS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/23/2026		D		3,244	D	(1)	13,925	D
Common Stock	03/23/2026		D		13,925	D	(2)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").

2. At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.

	/s/ Leslie Trigg by Mark Busch, attorney-in- fact	03/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Leslie Trigg report on the Exact Sciences (EXAS) Form 4?

Leslie Trigg reported disposing of all her Exact Sciences common shares back to the company. Two issuer dispositions on March 23, 2026 returned 3,244 and 13,925 shares, leaving her with zero directly held shares following the merger transaction with Abbott Laboratories.

How is the Abbott merger reflected in this Exact Sciences (EXAS) insider filing?

The filing records equity changes triggered automatically by the Abbott–Exact Sciences merger. At the merger’s effective time, each Exact Sciences common share was converted into the right to receive $105.00 in cash, and restricted shares were vested, cancelled, and similarly converted for cash.

What cash consideration did Exact Sciences (EXAS) shareholders receive in the Abbott deal?

Each outstanding Exact Sciences common share became entitled to $105.00 in cash. The merger agreement specified that, at the effective time, every issued and outstanding share converted into the right to receive $105.00 without interest, subject to the merger’s terms and conditions.

What happened to Exact Sciences (EXAS) restricted stock at the merger effective time?

Restricted Exact Sciences shares were fully vested, cancelled, and paid out in cash. Each share subject to vesting, repurchase, or other lapse restrictions under a company stock plan was deemed vested and converted into the $105.00 per-share cash merger consideration, less applicable tax withholding.

Does Leslie Trigg still hold Exact Sciences (EXAS) shares after the merger?

No, the Form 4 shows Leslie Trigg holding zero shares after the transactions. Following two issuer dispositions on March 23, 2026, her total directly owned Exact Sciences common stock position reported in the filing was reduced to zero shares.

Was this Exact Sciences (EXAS) Form 4 an open-market sale by the director?

No, the transactions are coded as dispositions to the issuer, not market sales. The code "D" and footnote language indicate the shares were returned to Exact Sciences as part of the cash merger mechanics with Abbott, rather than sold in open-market trading.